ESR1 and ovarian carcinoma: As for breast cancer, the progesterone receptor has been shown to be estrogen-regulated in ERα-positive ovarian carcinoma cells [33,100], and in the Phase II letrozole trial reported by Bowman et al. [85], higher progesterone receptor expression was associated with stable disease.